[go: up one dir, main page]

IN2012DN03387A - - Google Patents

Info

Publication number
IN2012DN03387A
IN2012DN03387A IN3387DEN2012A IN2012DN03387A IN 2012DN03387 A IN2012DN03387 A IN 2012DN03387A IN 3387DEN2012 A IN3387DEN2012 A IN 3387DEN2012A IN 2012DN03387 A IN2012DN03387 A IN 2012DN03387A
Authority
IN
India
Prior art keywords
naphtalen
hydroxycarbamoyl
benzamide
hydroxy
histone deacetylase
Prior art date
Application number
Inventor
Charles Dinarello
Gianluca Fossati
Paolo Mascagni
Original Assignee
Italfarmaco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco Spa filed Critical Italfarmaco Spa
Publication of IN2012DN03387A publication Critical patent/IN2012DN03387A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Herein disclosed is a method for treating patients affected by HIV comprising administering N-hydroxy-benzamide-based histone deacetylase inhibitors  such as: • diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxymethyl)-naphtalen-2-yl- methyl] -ammonium chloride; • 4-(2-(S)-benzoylamino-3-naphtalen-2-yl-propionylamino)-N-hydroxy- benzamide; and/or • benzo[l 3]dioxole-5-carboxylic acid [l(S)-(4-hydroxycarbamoyl- phenylcarbamoyl)-2-naphtalen-2-yl-ethyl]-amide. Such histone deacetylase inhibitors are administered in a dosage ranging from 50 to 200 mg/day  preferably from 100 to 200 mg/day  so as to obtain a blood concentration between 125 and 250 nM.
IN3387DEN2012 2009-10-23 2010-09-14 IN2012DN03387A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2009A001837A IT1396915B1 (en) 2009-10-23 2009-10-23 DIETYL- [6- (4-HYDROXICARBAMYL-PHENYL-CARBAMYLOSSIMETHYL) -NAFTALEN-2-IL-METHYL] -AMMONIUM CHLORIDE AND OTHER DERIVATIVES OF N-HYDROXY-BENZAMID FOR THE USE IN THE TREATMENT OF HIV INFECTIONS.
PCT/IB2010/054139 WO2011048514A1 (en) 2009-10-23 2010-09-14 Derivatives of n-hydroxybenzamide for treating hiv infections

Publications (1)

Publication Number Publication Date
IN2012DN03387A true IN2012DN03387A (en) 2015-10-23

Family

ID=42153811

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3387DEN2012 IN2012DN03387A (en) 2009-10-23 2010-09-14

Country Status (10)

Country Link
US (1) US8637702B2 (en)
EP (1) EP2490682A1 (en)
JP (1) JP5746196B2 (en)
KR (1) KR101687644B1 (en)
CN (1) CN102548551A (en)
BR (1) BR112012008780A2 (en)
CA (1) CA2773210C (en)
IN (1) IN2012DN03387A (en)
IT (1) IT1396915B1 (en)
WO (1) WO2011048514A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103974956B (en) * 2011-11-29 2016-07-06 南京奥昭生物科技有限公司 As HDAC6 inhibitor and the heterocyclic amide being used as antitumor agent
MX349767B (en) 2012-02-03 2017-08-11 Italfarmaco Spa Diethyl- [6- (4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl) - naphthalen-2-yl-methyl] -ammonium chloride for use in the treatment of muscular dystrophy.
IT201600074606A1 (en) * 2016-07-18 2018-01-18 Italfarmaco Spa New benzo-N-hydroxy amide compounds having antitumor activity
EP3525821A4 (en) 2016-10-17 2020-09-09 University of Maryland MULTISPECIFIC ANTIBODIES AGAINST HUMAN IMMUNDEFICIENCY VIRUS AND METHOD OF USING THEM
IT201900003281A1 (en) * 2019-03-06 2020-09-06 Chemi Spa Process to prepare high purity {6 - [(diethylamino) methyl] naphthalen-2-yl} methyl [4- (hydroxycarbamoyl) phenyl] carbamate
WO2022088047A1 (en) * 2020-10-30 2022-05-05 中国科学院深圳先进技术研究院 Application of itf2357 in preparation of drug for preventing and treating coronaviruses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283637B1 (en) 1996-05-14 1998-04-23 Italfarmaco Spa COMPOUNDS WITH ANTI-INFLAMMATORY AND IMMUNOSOPPRESSIVE ACTIVITY
ITMI20030025A1 (en) 2003-01-10 2004-07-11 Italfarmaco Spa HYDROXAMIC ACID DERIVATIVES FOR ANTI-INFLAMMATORY ACTIVITY.
ITMI20030063A1 (en) 2003-01-17 2004-07-18 Italfarmaco Spa HYDROXIDE MONOHYDRATE OF THE ESTER (6-DIETHYLAMINOMETHY-NAFTALEN-2-IL) METHYL OF CARBAMIC ACID (4-HYDROXICARBAMMOYL-FENYL).
EP1725098A2 (en) * 2004-03-18 2006-11-29 Samaritan Pharmaceuticals, Inc. Benzamide and benzoate anti-hiv compounds
ITMI20041347A1 (en) * 2004-07-05 2004-10-05 Italfarmaco Spa ALPHA-AMINO ACID DERIVATIVES FOR ANTI-INFLAMMATORY ACTIVITIES
US20100324034A1 (en) 2007-02-08 2010-12-23 Hazuda Daria J Methods of Using SAHA for Treating HIV Infection

Also Published As

Publication number Publication date
US20120203014A1 (en) 2012-08-09
CN102548551A (en) 2012-07-04
IT1396915B1 (en) 2012-12-20
US8637702B2 (en) 2014-01-28
EP2490682A1 (en) 2012-08-29
BR112012008780A2 (en) 2020-12-01
KR20120083356A (en) 2012-07-25
KR101687644B1 (en) 2016-12-19
CA2773210C (en) 2017-01-03
ITMI20091837A1 (en) 2011-04-23
JP5746196B2 (en) 2015-07-08
JP2013508349A (en) 2013-03-07
CA2773210A1 (en) 2011-04-28
WO2011048514A1 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
AR075204A1 (en) DPP-4 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, USEFUL TO TREAT METABOLIC DISEASES IN PEDIATRIC PATIENTS, PARTICULARLY MELLITUS DIABETES TYPE 2
IN2012DN03387A (en)
ECSP11011453A (en) TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALFA-7 NICOTINIC ACID RECEPTORS IN COMBINATION WITH ACETILCOLINESTERASE INHIBITORS
MX2012000275A (en) Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement.
MX2009003372A (en) Non-mucoadhesive film dosage forms.
EA201270144A1 (en) COMBINED THERAPY FOR TREATMENT OF DIABETES
EA201100778A1 (en) HETEROCYCLIC SUBSTITUTED COMPOUNDS AS HIF INHIBITORS
CL2011001178A1 (en) Use of (r) -7-chloro-niquinuclidin-3-1l) senzo [b] thiophene-2-carboxamide or a salt thereof or a pharmaceutical composition comprising it to prepare a useful medication to improve cognition in a patient suffering from Alzheimer's or schizophrenia.
MX2011011083A (en) Heterocyclic compounds as mek inhibitors.
EA200971086A1 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING SCHIZOPHRENIA
UA104148C2 (en) [4- (5-AMINOMETHYL-2-fluorophenyl) -piperidine-1-yl] - [7-fluorine-1- (2-methoxyethyl) -4-trifluoromethoxy-1H-indol-3-yl] -methanone as an inhibitor FAT CELLS
PH12012501358A1 (en) Treatment method
BR112014010729A2 (en) methods for treating gout attacks
WO2006017188A3 (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
TNSN08506A1 (en) Substituted carboxamides
MX341660B (en) Ghrelin receptor agonist for treatment of dyscrasia.
MX2014005400A (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent.
PH12014502282A1 (en) Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
DE602006017728D1 (en) CANCER TREATMENT BY AGENT AND 2-DEOXYGLUCOSE
RU2011123367A (en) METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRANE ETHEXILATE OR ITS SALT WITH IMPROVED EFFICIENCY COMPARED TO STANDARD TREATMENT OF WARFARINE
DE602007014193D1 (en) TREATMENT OF PSYCHIATRIC PATIENTS WITH SLEEP DISORDERS AND / OR EXCESSIVE TAGESSLESSNESS WITH PALIPERIDONE
GB0405381D0 (en) A method and means for treating heart failure
NZ602032A (en) Oral b12 therapy
MX2008011321A (en) Pharmaceutical composition for use in treating sexually transmitted infections.